Innovative Therapeutics in Oncology and Neuroscience
Promising Near-Term, Innovative Treatment Options
for Infectious Disease Franchise
NUZYRAⓇ
(amadacycline)
NUZYRA
Oral and IV Broad Spectrum Antibiotic
Unmet Medical Needs in China
Significant addressable markets: 10 million 1 CABP and
2.8 million 1 ABSSSI incidence every year
Unmet needs for broad-spectrum antibiotics addressing
MDR with favorable safety profile
Differentiation
Broad-spectrum IV/PO new-generation tetracycline,
reducing exposure to hospital pathogens and
associated costs with hospital stays
Clear differentiation vs. older generics and other
drugs from the tetracycline class
Classified as Category 1 innovative drug in China
Dec 2021 China Commercial Launch²
Sulbactam-Durlobactam
Best-in-Class Class A, C & D ẞ Lactamase Coverage
Unmet Medical Needs in China
•
-
China: 300,000 Acinetobacter infections reported in
mainland China in 20223
Increasing Burden, Limited Treatment, High Mortality
Unique activity against Acinetobacter and CRAB
High carbapenem-resistant rate: >53% (CARSS) and
~80% (CHINET); antibiotic resistance is increasing 3,4
Most common pathogen causing HABP/VABP
in China5
⚫ Limited therapeutic options Polymyxin-based
polypharmacy Colistin: drug of last resort
Mortality -43% with best available therapy6
Feb 2023 China NDA Acceptance
Abbreviations: hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP).
Sources: Entasis Therapeutics corporate presentation, 2021; U.S. Centers for Disease Control and Prevention. Zai Lab analysis.
Notes: (1) 2020 estimates, Zai Lab analysis; (2) Signed contract sales agreement with Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd., a direct wholly-owned subsidiary of Hanhui Pharmaceutical Co., Ltd; (3) 2022 Report of China
Antimicrobial Resistance Surveillance System (CARSS) published in November 2023; (4) 2023 Report of China Antimicrobial Surveillance Network (CHINET); (5) China Diagnosis and Treatment Guideline for hospital-acquired pneumonia and
ventilator-associated pneumonia, 2018; (6) Mohd Sazlly Lim S, et al. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A
42 systematic review and meta-analysis. J Infect. 2019 Dec;79(6):593-600.
Clinical Data -
Anti-infectiveView entire presentation